Quantifying the indirect treatment effect via surrogate markers

Statistics in Medicine

Volumn 25, Issue 2, 2006, Pages 223-231

  Qu, Yongming ^a   Case, Michael ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Path analysis; Surrogate markers; Treatment effect

Indexed keywords

PLACEBO; RALOXIFENE;

ANALYTIC METHOD; ARTICLE; BONE DENSITY; CLINICAL TRIAL; DISEASE MARKER; DRUG EFFICACY; HUMAN; PATH ANALYSIS; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL MODEL; VERTEBRA FRACTURE;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN; COLLAGEN TYPE I; DATA INTERPRETATION, STATISTICAL; FRACTURES, BONE; OSTEOCALCIN; OSTEOPOROSIS; PEPTIDES; PROPORTIONAL HAZARDS MODELS; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS;

EID: 31344448504     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2176     Document Type: Article

References (14)

1. Reginster JY, Minne HW, Sorensen OH et al. Osteoporosis International 2000; 11:83-91.
2. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In Clinical Measurement in Drug Evaluation, Nimmo WS, Tucker GT (eds). Wiley: New York, 1995.
3. Prentice RL. Surrogate endpoints in clinical trials: definitions and operational criteria. Statistics in Medicine 1989; 8:431-440.
4. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Statistics in Medicine 1992; 11:167-178.
5. Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Statistics in Medicine 2001; 20:3175-3188.
6. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Annals of Internal Medicine 1996; 125:605-613.
7. Chen C, Wang H, Snapinn SM. Proportion of treatment effect (PTE) explained by a surrogate marker. Statistics in Medicine 2003; 22:3449-3459.
8. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. Journal of Bone and Mineral Research 2002; 17:1-10.
9. Khosla S. Surrogates for fracture endpoints in clinical trials. Journal of Bone and Mineral Research 2003; 18:1146-1149.
10. Wright S. The method of path coefficients. Annals of Mathematical Statistics 1934; 5:161-215.
11. Alwin DF, Hauser RM. The decomposition of effects in path analysis. American Sociological Review 1975; 40:37-47.
12. Retherford RD, Choe MK. Statistical Models for Causal Analysis. Wiley: New York, 1993.
13. Lu Y. An application of path analysis in the design of clinical trials. American Statistical Association Proceedings, 2003.
14. Gografos K. On a measure of dependence based on Fisher's information matrix. Communications in Statistics - Theory and Methods 1998; 27:1715-1728.